Filing Details
- Accession Number:
- 0000950170-24-139069
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-12-20 16:25:29
- Reporting Period:
- 2024-12-18
- Accepted Time:
- 2024-12-20 16:25:29
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1936258 | Newamsterdam Pharma Co N.v. | NAMS | () | P7 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1823747 | U.a. Cooperatief Iv Fund Capital Forbion | C/O Forbion Capital Partners, Gooimeer 2-35 Narden P7 1411 DC | No | No | No | No | |
1911047 | U.a. Cooperatief I Fund Opportunities Growth Forbion | C/O Forbion Capital Partners, Gooimeer 2-35 Narden P7 1411 DC | No | No | No | No | |
1918318 | B.v. Management Growth Forbion | C/O Forbion Capital Partners, Gooimeer 2-35 Narden P7 1411 DC | No | No | No | No | |
2005384 | B.v. Management Iv Forbion | C/O Forbion Capital Partners, Gooimeer 2-35 Narden P7 1411 DC | No | No | No | No | |
2005407 | B.v. Nap Forgrowth | C/O Forbion Capital Partners, Gooimeer 2-35, Naarden P7 1411 DC | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Ordinary Shares | Disposition | 2024-12-18 | 54,518 | $25.72 | 10,954,712 | No | 4 | S | Indirect | See footnote |
Ordinary Shares | Disposition | 2024-12-18 | 46,210 | $26.55 | 10,908,502 | No | 4 | S | Indirect | See footnote |
Ordinary Shares | Disposition | 2024-12-19 | 56,506 | $25.45 | 10,851,996 | No | 4 | S | Indirect | See footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | See footnote |
No | 4 | S | Indirect | See footnote |
No | 4 | S | Indirect | See footnote |
Footnotes
- This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by NAP PoolCo B.V. ("PoolCo") on March 28, 2024.
- Represents 23,944 shares sold on behalf of Forbion Growth Opportunities Fund I Cooperatief U.A. ("Forbion Growth I") and 30,574 shares sold on behalf of Forbion Capital Fund IV Cooperatief U.A. ("Forbion IV"). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.165 to $26.155. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- (Continued from footnote 2) Following the reported transaction, of the 10,954,712 Ordinary Shares beneficially owned by ForGrowth NAP B.V. ("ForGrowth"), 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,302,539 are held by PoolCo and are allocated to ForGrowth, of which 4,158,830 shares are beneficially owned by Forbion Growth I and 6,143,709 shares are beneficially owned by Forbion IV.
- ForGrowth is a shareholder of PoolCo. ForGrowth is a joint investment vehicle wholly owned by Forbion Growth I and Forbion IV but does not exercise voting or dispositive power over the Ordinary Shares held on behalf of Forbion Growth I and Forbion IV. Forbion IV Management B.V. is the sole director of Forbion IV and Forbion Growth Management B.V. is the sole director of Forbion Growth I. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose.
- Represents 20,295 shares sold on behalf of Forbion Growth I and 25,915 shares sold on behalf of Forbion IV. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.165 to $26.88. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 10,908,502 Ordinary Shares beneficially owned by ForGrowth, 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,256,329 are held by PoolCo and are allocated to ForGrowth, of which 4,138,535 shares are beneficially owned by Forbion Growth I and 6,117,794 shares are beneficially owned by Forbion IV.
- Represents 24,817 shares sold on behalf of Forbion Growth I and 31,689 shares sold on behalf of Forbion IV. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.94. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 10,851,996 Ordinary Shares beneficially owned by ForGrowth, 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,199,823 are held by PoolCo and are allocated to ForGrowth, of which 4,113,718 shares are beneficially owned by Forbion Growth I and 6,086,105 shares are beneficially owned by Forbion IV.